Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online

55,000 vials of peptides will be produced from this production suite and are pre-sold Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September MEQUON, Wis., Aug. 24, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp....